This site is intended for health professionals only

Published on 14 April 2010

Share this story:
Twitter
LinkedIn

Once-a-day pill “cuts MS relapse”

teaser

Relapse rates in multiple sclerosis patients have been cut significantly by a once-a-day pill, according to a study by Novartis.

A two-year trial indicated that the pill Gilenia cut the rate of relapse by 62% in patients who had not been treated before, compared with trial participants who were given a placebo. MS patients who had previously been receiving treatment had their annual relapse rate cut by 44%, according to Switzerland-based corporation Novartis.

The findings, which were presented to the American Academy of Neurology, also indicated that Gilenia delayed the progression of disability by 30%, compared with those receiving placebos, after two years. The drug also apparently reduced the number of brain lesions from MRI, compared with those who took interferon beta-1a but had then switched to Gilenia.

MS affects people differently: some people are left permanently disabled by the condition, while others can experience only mild symptoms.

People with MS can experience numbness in their body; tingling or pain; a sensation of electric shock if the head is moved a certain way; weakness in limbs; partial or complete sight loss; unsteady walking and tremors.

Copyright Press Association 2010
American Academy of Neurology



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn